AskMed

Atorvastatin: Uses, How It Works and How Long to Take It

Atorvastatin is a prescription statin, sold as Lipitor and as generic tablets, that lowers LDL cholesterol by blocking an enzyme the liver uses to make cholesterol. It is used for two linked purposes: treating raised cholesterol, including inherited forms such as familial hypercholesterolemia, and lowering the risk of heart attack, stroke and procedures to reopen blocked arteries. Guidelines give it to people who already have cardiovascular disease (secondary prevention) and to people at raised risk who don't have it yet (primary prevention). This guide explains how atorvastatin works, what its FDA label covers, how the 2018 ACC/AHA cholesterol guideline and NICE guideline NG238 decide who takes it, how much LDL lowering to expect, when lipids are rechecked and how long treatment lasts.

For clinicians and students, the harder question is rarely what atorvastatin does but which recommendation fits a given patient, because the US and UK guidelines draw their lines in different places and in different units. AskMed is a medical question app made for doctors, nurses, pharmacists, medical students and researchers. Instead of answering from memory, it searches clinical guidelines, journals and drug labels first, then writes an answer with a link after every claim. Ask it which ACC/AHA statin benefit group a 62-year-old with type 2 diabetes and an LDL-C of 120 mg/dL falls into, and it sets out the matching recommendation with the guideline section linked.

Ask AskMed which statin benefit group fits your patient:

What kind of drug is atorvastatin, and how does it work?

Atorvastatin belongs to the statins, a drug class whose formal name is HMG-CoA reductase inhibitors. Its FDA label describes atorvastatin as a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, an early building block of cholesterol. The label names the liver as the primary site of action and the main site of both cholesterol synthesis and LDL clearance. In animal models, the label adds, atorvastatin lowers plasma cholesterol in two ways: by blocking cholesterol synthesis in the liver, and by increasing the number of LDL receptors on liver cells, which take up more LDL particles from the blood and break them down. It also reduces LDL production and the number of LDL particles. MedlinePlus puts the same effect in plain words: atorvastatin slows how much cholesterol the body makes, which limits the build-up of cholesterol and fats in the walls of the arteries.

  1. Enzyme blocked: atorvastatin inhibits HMG-CoA reductase in liver cells.
  2. Less cholesterol made: the liver makes less cholesterol of its own.
  3. More LDL receptors: liver cells put more LDL receptors on their surface.
  4. Lower LDL-C: more LDL is cleared from the blood, so LDL cholesterol falls.
How atorvastatin lowers LDL cholesterol, from section 12.1 of the LIPITOR FDA label.

The clinical point of lowering LDL is fewer heart attacks and strokes, and the size of that benefit tracks the size of the LDL reduction. The Cholesterol Treatment Trialists' (CTT) Collaboration pooled individual data from 26 randomized statin trials with about 170,000 participants and found that each 1.0 mmol/L reduction in LDL cholesterol lowered the rate of major vascular events by about a fifth (rate ratio 0.78) and all-cause mortality by about a tenth (rate ratio 0.90), with no increase in cancer or in deaths from other non-vascular causes (Lancet, 2010).

What is atorvastatin used for?

Atorvastatin is used for two connected purposes in its FDA label: lowering the risk of cardiovascular events, and lowering LDL cholesterol in specific lipid disorders. The first group of indications covers adults with multiple risk factors for coronary heart disease but no clinically evident disease, adults with type 2 diabetes and multiple risk factors, and adults who already have clinically evident coronary heart disease. In these adults atorvastatin reduces the risk of heart attack and stroke and, depending on the group, of revascularization procedures, angina and hospitalization for heart failure. The second group uses atorvastatin as an adjunct to diet to lower LDL cholesterol in adults with primary hyperlipidemia and in adults and children aged 10 years and older with heterozygous familial hypercholesterolemia. In homozygous familial hypercholesterolemia, also from age 10, atorvastatin is added to other LDL-lowering treatments. The label also lists primary dysbetalipoproteinemia and hypertriglyceridemia in adults, again alongside diet.

The NHS describes the same two roles in everyday terms: atorvastatin treats high cholesterol and helps prevent heart attacks and strokes, and it may be prescribed for people with diabetes, kidney disease or familial hypercholesterolaemia. Who actually receives it is decided by guidelines, which the next two sections cover.

Who takes atorvastatin under the ACC/AHA cholesterol guideline?

The 2018 AHA/ACC multisociety guideline on the management of blood cholesterol, led by Grundy and published in Circulation, sorts adults into groups that benefit from statin therapy, and atorvastatin is one of the two statins its intensity table lists as high-intensity therapy, alongside rosuvastatin; atorvastatin also appears in the moderate-intensity column. In secondary prevention, patients with clinical atherosclerotic cardiovascular disease (ASCVD) receive high-intensity or maximally tolerated statin therapy, aiming to lower LDL-C by 50% or more. In very high-risk ASCVD, an LDL-C of 70 mg/dL (1.8 mmol/L) or above on that therapy is the threshold for considering a nonstatin add-on. In primary prevention, adults with severe primary hypercholesterolemia, an LDL-C of 190 mg/dL or higher, start high-intensity statin therapy without a 10-year risk calculation. Adults aged 40 to 75 with diabetes and an LDL-C of 70 mg/dL or higher start moderate-intensity statin therapy, again without calculating risk.

For that last group, the guideline asks for a clinician-patient risk discussion before a statin is started. At a 10-year ASCVD risk of 7.5% or more, it starts a moderate-intensity statin if the discussion favours treatment, aiming for an LDL-C reduction of 30% or more; at a risk of 20% or more the aim is a reduction of 50% or more. In the borderline (5% to under 7.5%) and intermediate (7.5% to under 20%) bands, risk-enhancing factors favour starting a statin. When the decision is still uncertain, a coronary artery calcium score of 100 Agatston units or more, or at or above the 75th percentile, points toward statin therapy. Over age 75, the guideline notes that randomized trial evidence for statins is less strong, so clinical assessment of risk status carries more weight.

How does NICE NG238 use atorvastatin?

NICE guideline NG238, Cardiovascular disease: risk assessment and reduction, including lipid modification, published in 2023, replaced the 2014 guideline CG181 and makes atorvastatin the statin it offers first in most situations in England and Wales. In primary prevention, NICE estimates 10-year risk with the QRISK3 calculator and offers atorvastatin to adults with a QRISK3 score of 10% or more, once lifestyle changes have been discussed and the decision is shared and informed. A score under 10% does not rule a statin out when the person has an informed preference for one or there is concern that the score underestimates risk. NICE does not use a risk calculator for people with type 1 diabetes, chronic kidney disease (an eGFR under 60 mL/min/1.73 m² and/or albuminuria) or familial hypercholesterolaemia, who are already at high risk, and it offers atorvastatin for primary or secondary prevention in chronic kidney disease. People aged 85 or over can be considered at increased risk because of age alone.

In secondary prevention, NICE starts a high-intensity statin without waiting for lifestyle measures to work, and NG238 added a new lipid target for adults on treatment: an LDL cholesterol of 2.0 mmol/L or less, or a non-HDL cholesterol of 2.6 mmol/L or less. For type 1 diabetes, NICE offers a statin to adults who are over 40, have had diabetes for more than 10 years, have established nephropathy or have other cardiovascular risk factors, and suggests considering one in adults aged 18 to 40.

Set side by side, the two guidelines rarely disagree on who benefits, but they differ in the 10-year risk tool, the threshold (7.5% versus 10%), the units (mg/dL versus mmol/L) and whether treatment is judged by percentage reduction or by a target level. That makes a cross-guideline question hard to answer from memory. In AskMed you can ask how the NICE NG238 secondary prevention target of an LDL cholesterol of 2.0 mmol/L or less compares with the ACC/AHA threshold for adding a nonstatin, and get both statements with their sources linked.

Compare the NICE and ACC/AHA lipid recommendations in AskMed:

How much does atorvastatin lower LDL cholesterol?

How much atorvastatin lowers LDL cholesterol depends mainly on the intensity prescribed, and the 2018 ACC/AHA guideline defines intensity by the expected percentage fall in LDL-C. High-intensity statin therapy typically lowers LDL-C by 50% or more, moderate-intensity therapy by 30% to 49%, and low-intensity therapy by less than 30%. Atorvastatin is listed in both the high-intensity and the moderate-intensity columns of the guideline's table, so the same drug can be used for either goal. The FDA label adds that the prescribed amount, rather than the concentration of the drug in the blood, correlates better with LDL-C reduction, and that treatment should be individualized on the basis of the patient's response. NICE frames the expected effect in non-HDL cholesterol: in the NHS pathway built on NG238, high-intensity statin treatment should reduce non-HDL cholesterol by more than 40% from baseline, and a smaller fall prompts a review rather than an automatic change of drug.

Expected LDL-C reduction (ACC/AHA 2018) Low Moderate High 0% 30% 50% Under 30% 30% to 49% 50% or more Atorvastatin: moderate or high intensity
Statin intensity bands as defined by the 2018 AHA/ACC cholesterol guideline. Individual responses vary, which is why the guideline checks the percentage response after starting.

The percentage is measured against the patient's own starting value, so a baseline lipid profile before atorvastatin is started is what makes the later result interpretable.

When are cholesterol levels checked after starting atorvastatin?

Cholesterol levels are usually checked a few weeks to a few months after atorvastatin is started, and the exact window depends on the source. The FDA label says to assess LDL-C when clinically appropriate, as early as 4 weeks after starting atorvastatin, and to adjust treatment if necessary. The 2018 ACC/AHA guideline asks clinicians to assess adherence and the percentage response to LDL-C-lowering medicines and lifestyle changes with a repeat lipid measurement 4 to 12 weeks after a statin is started or its dose is adjusted, then every 3 to 12 months as needed. NICE's approach, as set out in the NHS pathway built on NG238, is a repeat full lipid profile, which can be non-fasting, 2 to 3 months after starting or changing treatment, together with liver transaminases, followed by an annual medication review that covers effectiveness, adherence and side effects. On liver tests, the FDA label says to consider testing before starting atorvastatin and when clinically indicated afterwards.

When the response falls short, the first steps in both systems are the same: ask about adherence and timing, and review diet and lifestyle before changing treatment. After that, the options include a higher intensity, a different statin, or adding a nonstatin such as ezetimibe, guided by the patient's risk. If you are a clinician or student working through a review, AskMed lets you set out the whole picture, such as a patient with established coronary disease whose non-HDL cholesterol fell by only a quarter on high-intensity atorvastatin, and ask what NICE NG238 recommends next, with each step linked to its source.

Work through a statin review in AskMed:

How long do people take atorvastatin?

Most people take atorvastatin for a long time, often for the rest of their lives, because its benefit lasts only while LDL cholesterol stays lower. The NHS page on atorvastatin says you usually need to take it for a long time, sometimes for life, and that stopping without medical advice can let cholesterol rise again. The NHS page on statins says the same of the whole class: statins are usually taken long term, and anyone thinking of stopping should first talk to a doctor or pharmacist. MedlinePlus advises continuing atorvastatin even when feeling well, and not stopping it without talking to a doctor. The guidelines are built around ongoing treatment too: the 2018 ACC/AHA guideline keeps monitoring every 3 to 12 months as needed after the first check, and NICE expects an annual review for everyone taking a statin. The CTT meta-analysis found no lower threshold within the cholesterol range studied below which further LDL lowering stopped reducing risk.

Some situations change the plan. The FDA label says atorvastatin should be stopped when pregnancy is recognized and that breastfeeding is not recommended during treatment, and the NHS advises stopping before trying for a baby. In people over 75, the ACC/AHA guideline relies more on clinical judgement because trial evidence is less strong. Anyone who wants to stop should discuss it first rather than stopping alone.

Side effects and interactions: the basics

The FDA label for atorvastatin lists the adverse reactions seen in at least 2% of trial patients and more often than with placebo, including nasopharyngitis, joint pain, diarrhea, pain in the limbs, urinary tract infection, indigestion, nausea, muscle pain and spasms, and insomnia. The label's warnings cover four areas: myopathy and rhabdomyolysis; immune-mediated necrotizing myopathy, a rare autoimmune muscle disease; liver dysfunction; and increases in HbA1c and fasting glucose. The label names the risk factors for muscle problems as age 65 or older, uncontrolled hypothyroidism, renal impairment, some other medicines, including other lipid-lowering drugs, and higher dosage. Atorvastatin must not be used in acute liver failure or decompensated cirrhosis, or with hypersensitivity to the drug. Unexplained muscle pain, tenderness or weakness, especially with fever or unusual tiredness, dark urine, yellowing of the skin or eyes, or signs of an allergic reaction need prompt medical attention.

For interactions, the label names cyclosporine, gemfibrozil, certain HIV and hepatitis C protease inhibitors, clarithromycin, erythromycin and azole antifungals such as itraconazole as raising the risk of muscle injury, along with colchicine, niacin, other fibrates and large amounts of grapefruit juice; rifampin lowers atorvastatin exposure, and atorvastatin raises digoxin and oral contraceptive levels. A raised ALT on a statin is a common worry; our guide to elevated ALT levels covers what the liver guidance says about it.

Frequently asked questions

What is atorvastatin used for?

Atorvastatin is used to lower LDL cholesterol and to reduce the risk of heart attack, stroke and related events. Its FDA label covers adults at raised cardiovascular risk, adults with type 2 diabetes and risk factors, adults with coronary heart disease, and several lipid disorders, including familial hypercholesterolemia from age 10.

Is atorvastatin a statin?

Yes. Atorvastatin is a statin, or HMG-CoA reductase inhibitor. It blocks the enzyme the liver uses to make cholesterol, which leads liver cells to take up more LDL from the blood.

How soon does atorvastatin lower cholesterol?

The FDA label allows LDL-C to be checked as early as 4 weeks after starting. The ACC/AHA guideline rechecks lipids 4 to 12 weeks after starting, and NICE 2 to 3 months after starting, to confirm the expected response.

Is atorvastatin used for primary or secondary prevention?

Both. It is used after a heart attack, stroke or other atherosclerotic disease (secondary prevention) and in people at raised risk who have not had an event (primary prevention), such as a QRISK3 score of 10% or more under NICE.

Do people take atorvastatin for life?

Often, yes. The NHS says atorvastatin is usually taken for a long time, sometimes for life, and that cholesterol can rise again if it is stopped. Any change should be discussed with the prescriber first.

Sources

  1. Viatris Specialty LLC. LIPITOR (atorvastatin calcium) tablets, prescribing information. DailyMed, US National Library of Medicine. Revised April 2024.
  2. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082-e1143.
  3. National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238). 2023.
  4. NHS Specialist Pharmacy Service. Cardiovascular disease: risk assessment and reduction, including lipid modification, updated guidance (NG238).
  5. NHS Humber and North Yorkshire Integrated Care Board. Guidance for lipid management for primary and secondary prevention of CVD, based on NICE NG238. Approved June 2025.
  6. NHS. Atorvastatin.
  7. NHS. Statins.
  8. MedlinePlus, US National Library of Medicine. Atorvastatin.
  9. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681.

Cited medical answers
you can trust.

AskMed on iPhone, iPad, Android and the web.